MedTrace Logo

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

NCT00752037 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-07-20

No results posted yet for this study

Summary

A single center, open label, 48-week study of lopinavir/ritonavir in combination with raltegravir. 30 patients, both naïve and experienced, will be enrolled. 15 treatment naïve patients and 15 treatment experienced patients enrolled

Conditions

  • HIV Infections

Interventions

DRUG

lopinavir/ritonavir and raltegravir

lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Saint Michael's Medical Center

    lead OTHER

Principal Investigators

  • Jihad Slim, MD · Saint Michael's Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-04-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00752037 on ClinicalTrials.gov